Welcome to our dedicated page for LENZ Therapeutics SEC filings (Ticker: LENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LENZ Therapeutics, Inc. filings document the company’s transition from ophthalmic product development to commercialization of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults. Form 8-K disclosures cover financial results, FDA approval and U.S. availability of VIZZ, product launch updates, safety-related communications, and capital-raising activity under an at-the-market sales agreement.
The company’s proxy and governance materials address shareholder voting matters, executive and board governance, material agreements, capital-structure disclosure, and operating and financial results. The filing record also captures regulatory and commercial disclosures tied to VIZZ, including product approval, launch-stage operations, financing transactions, and risk-related information relevant to a pharmaceutical company commercializing an ophthalmic prescription product.
LENZ Therapeutics Chief Financial Officer Daniel R. Chevallard received new equity awards. On January 2, 2026, he was granted a stock option for 84,200 shares of LENZ Therapeutics, Inc. common stock at an exercise price of $16 per share, with no cash paid for the option itself.
The filing also reports a grant of 14,000 restricted stock units, each representing one share of common stock. Both the option and RSUs vest over time starting from January 2, 2026, and vesting is conditioned on Mr. Chevallard continuing to serve as a Service Provider under the company’s 2024 Equity Incentive Plan.
LENZ Therapeutics described a recently reported retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44% that was submitted to the FDA’s FAERS database. The company notes that FAERS data alone do not prove a causal relationship, but it reviewed the case under its pharmacovigilance procedures.
The patient had extensive prior retinal problems, including bilateral lattice degeneration, past peripheral laser treatment, and a previous retinal tear, and had not recently undergone a peripheral retinal exam before starting VIZZ. Several days after beginning therapy, on a non-dosing day, the patient noticed vision changes, was diagnosed with a retinal tear, treated with laser retinopexy, and is recovering well. Independent retina specialists highlighted multiple pre-existing risk factors, so any link to VIZZ remains uncertain. Retinal tears naturally occur at about 25 per 100,000 people per year, and this initial report does not change the company’s current safety expectations for VIZZ.
LENZ Therapeutics, Inc. (LENZ) reported a Form 4 for its Chief Commercial Officer, who executed an option exercise and related stock sales on 11/17/2025. The officer exercised a stock option to acquire 10,000 shares of common stock at $2.08 per share, then sold 4,212 shares at a weighted average price of $25.7385 and 5,788 shares at a weighted average price of $26.3669. After these transactions, the officer directly held 4,733 shares of common stock and 53,241 stock options. The sales were made under a Rule 10b5-1 trading plan entered into on August 12, 2025, which is a pre-arranged plan intended to structure trading in advance.
LENZ Therapeutics disclosed an insider purchase. A Director bought 10,500 shares of common stock on 11/07/2025 at a weighted-average price of $22.7884. After the transaction, the Director beneficially owns 10,500 shares directly and 620,599 shares indirectly through a trust. The indirect holdings include 95,034 shares transferred to the McCollum Living Trust on June 6, 2024.
LENZ Therapeutics (LENZ) reported an insider purchase by its Chief Financial Officer, Daniel R. Chevallard. On 11/07/2025, he bought common stock in two open‑market transactions coded “P”: 20 shares at $22.71 and 2,178 shares at $22.7561. Following these trades, he directly owns 5,386 shares.
LENZ Therapeutics (LENZ) reported Q3 2025 results and highlighted FDA approval of VIZZ. The company recorded $12.5 million in license revenue in the quarter and $17.5 million year-to-date. Operating expenses rose with commercialization activities, led by selling, general and administrative of $27.6 million and research and development of $3.8 million, resulting in a net loss of $16.7 million (basic and diluted loss per share of $0.59).
LENZ ended September 30, 2025 with $202.2 million in cash, cash equivalents, and marketable securities and reported 28,540,519 weighted‑average shares outstanding for the quarter. The company sold 920,500 shares via its at‑the‑market program during the nine months ended September 30, 2025 for $26.1 million in net proceeds, and subsequently sold 2,698,134 shares in October at a weighted‑average price of $45.79. On July 31, 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults.
LENZ Therapeutics, Inc. furnished a Form 8-K announcing its financial results for the quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, and incorporated by reference.
The Item 2.02 disclosure and the press release are furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act. Exhibits include the press release (99.1) and the cover page interactive data file (104).
Lenz Therapeutics, Inc. reported that it sold 1,748,634 shares of common stock on October 7, 2025 at a purchase price of $45.75 per share in a block trade to a single investor. The transaction generated gross proceeds of approximately $80,000,000 for the company. The sale was executed under the company’s existing “at the market” Sales Agreement with TD Securities (USA) LLC, dated April 4, 2025, and was completed pursuant to the terms of that agreement.
Versant entities reported insider sales of 224,974 shares of LENZ Therapeutics, Inc. (LENZ) on 09/30/2025. The Form 4 shows multiple sales by related reporting persons (including Versant Venture Capital VI, L.P. and affiliated Versant GP and Vantage entities) executed at weighted-average prices in ranges of $45.00–$45.99, $46.00–$46.99, and $47.00–$47.02. Post-transaction beneficial ownership amounts are disclosed for direct and indirect holdings, with several Versant entities retaining substantial positions (for example, 1,133,842 shares reported as directly owned by one entity and 842,162 shares indirectly held by another). The filing is signed by Max Eisenberg for the Versant reporting entities on 10/02/2025. The footnotes explain that reported prices are weighted averages from multiple transactions and identify the chain of general partners that may share voting and investment power over the disclosed holdings.
LENZ Therapeutics announced that VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop approved in the United States for treating presbyopia in adults, is now available. This medicine is intended to help adults with age-related difficulty focusing on near objects.
LENZ has begun distributing professional product samples nationwide through its sales force to optometrists and ophthalmologists so eye-care professionals can evaluate and introduce VIZZ to patients. Commercial product shipments to consumers will begin in October through an ePharmacy partner and are expected to expand to broad retail pharmacy availability by mid‑Q4 2025.